Last 17 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 26.08 | 11.48 | 12.60 | 10.65 | 9.37 | 5.77 | 4.48 | 5.34 | 7.80 | 7.87 | 7.90 | 7.91 | 12.27 | — | — | — | — | — |
| — | +99.2% | +181.2% | +99.4% | +20.2% | -26.7% | -43.3% | -32.5% | -36.4% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 19.93 | 13.15 | 14.10 | 12.13 | 13.32 | 4.85 | 62.08 | 7.86 | — | — | — | — | — | — | — | — | — | — |
| — | +171.3% | -77.3% | +54.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.2% | 85.9% | 86.4% | 85.4% | 83.3% | 83.6% | 84.4% | 86.2% | 85.4% | 88.0% | 88.4% | 86.4% | 85.9% | 89.5% | 88.1% | 87.7% | 89.1% | 85.1% |
| — | +2.7% | +2.4% | -0.9% | -2.5% | -5.0% | -4.5% | -0.2% | -0.5% | -1.7% | +0.3% | -1.5% | -3.6% | +5.1% | — | — | — | — | |
| Operating Margin | -219.4% | -110.2% | -108.3% | -177.3% | -258.8% | -192.1% | -256.2% | -192.7% | -247.7% | -360.9% | -283.3% | -305.4% | -633.0% | -173.0% | -111.3% | -160.9% | -194.4% | -180.2% |
| — | +42.7% | +57.8% | +8.0% | -4.5% | +46.8% | +9.6% | +36.9% | +60.9% | -108.6% | -154.5% | -89.9% | -225.6% | +4.0% | — | — | — | — | |
| Net Margin | -218.5% | -118.1% | -109.5% | -176.5% | -261.6% | -189.1% | -254.4% | -190.2% | -263.3% | -477.1% | -328.0% | -999.8% | -1806.5% | -346.1% | -270.0% | -2.2% | -336.1% | -182.6% |
| — | +37.6% | +56.9% | +7.2% | +0.6% | +60.4% | +22.4% | +81.0% | +85.4% | -37.9% | -21.5% | -44875.4% | -437.5% | -89.5% | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -285.4% | -36.5% | -38.5% | -60.1% | -64.9% | -74.9% | -195.9% | -1057.6% | — | — | — | — | — | — | — | — | — | — |
| — | +51.3% | +80.3% | +94.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -139.8% | -24.3% | -23.3% | -28.1% | -33.0% | -33.4% | -58.5% | -49.1% | -93.0% | -163.0% | -291.5% | -608.8% | -621.5% | -143.4% | -142.1% | -1.0% | -198.8% | -112.1% |
| — | +27.3% | +60.3% | +42.8% | +64.5% | +79.5% | +79.9% | +91.9% | +85.0% | -13.7% | -105.1% | -62724.2% | -212.7% | -27.9% | — | — | — | — | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.04 | 0.06 | 0.12 | 0.21 | 0.11 | 1.50 | 0.23 | — | — | — | — | — | — | — | — | — | — |
| — | -63.2% | -95.9% | -46.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.05 | 3.04 | 2.89 | 2.05 | 1.58 | 2.82 | 1.21 | 1.75 | 0.24 | 0.28 | 0.11 | 0.13 | 0.43 | 0.03 | 0.05 | 0.07 | 0.06 | 0.34 |
| — | +7.8% | +139.3% | +17.1% | +568.2% | +914.1% | +1031.4% | +1262.7% | -44.6% | +797.6% | +95.7% | +88.2% | +620.7% | -91.0% | — | — | — | — | |
| Quick Ratio | 1.96 | 2.95 | 2.81 | 1.96 | 1.55 | 2.76 | 1.19 | 1.74 | 0.23 | 0.27 | 0.10 | 0.12 | 0.41 | 0.03 | 0.05 | 0.06 | 0.05 | 0.32 |
| — | +6.8% | +135.7% | +13.0% | +577.5% | +914.5% | +1072.8% | +1377.8% | -44.6% | +904.9% | +119.5% | +91.1% | +710.7% | -91.5% | — | — | — | — | |
| Interest Coverage | -104.46 | -104.37 | -66.26 | -58.67 | -70.57 | -124.83 | -1017.63 | -603.81 | -15.63 | -19.19 | -42.96 | -234.65 | -5.02 | -1.06 | 0.23 | 0.94 | -16.81 | -69.15 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 17 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NRXS stock.
NeurAxis, Inc.'s current P/E is -7.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
NeurAxis, Inc.'s current operating margin is -219.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NeurAxis, Inc.'s business trajectory between earnings reports.